96-27022. National Environmental Policy Act; Proposed Revision of Policies and Procedures; Reopening of Comment Period as to Specific Documents  

  • [Federal Register Volume 61, Number 205 (Tuesday, October 22, 1996)]
    [Proposed Rules]
    [Pages 54746-54747]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 96-27022]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
     21 CFR Part 25
    
    [Docket No. 96N-0057]
    
    
    National Environmental Policy Act; Proposed Revision of Policies 
    and Procedures; Reopening of Comment Period as to Specific Documents
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Proposed rule; reopening of comment period.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is reopening to 
    November 22, 1996, the comment period on specific information that 
    supports certain categorical exclusions proposed by FDA in the proposed 
    rule entitled ``National Environmental Policy Act; Proposed Revision of 
    Policies and Procedures.'' The proposal was published in the Federal 
    Register of April 3, 1996 (61 FR 14922) (republished on May 1, 1996 (61 
    FR 19476)). FDA is reopening the comment period for 30 days for the 
    sole purpose of inviting public comments on those categorical 
    exclusions for which information has been added to the administrative 
    record.
    
    DATES: Written comments must be received by or postmarked on or before 
    November 21, 1996. Comments postmarked after such date will not be 
    considered.
    
    ADDRESSES: Submit written comments to the Dockets Management Branch 
    (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, 
    Rockville, MD 20857.
    
    FOR FURTHER INFORMATION CONTACT: 
        For information regarding human drugs: Nancy B. Sager, Center for 
    Drug Evaluation and Research (HFD-357), Food and Drug Administration, 
    5600 Fishers Lane, Rockville, MD 20857, 301-594-5721.
        For information regarding biologics: Nancy A. Roscioli, Center for 
    Biologics Evaluation and Research (HFM-205), Food and Drug 
    Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-3031.
        For information regarding veterinary medicines: Charles E. Eirkson, 
    Center for Veterinary Medicine (HFV-150), Food and Drug Administration, 
    7500 Standish Pl., Rockville, MD 20855, 301-594-1683.
        For information regarding foods: Buzz L. Hoffmann, Center for Food 
    Safety and Applied Nutrition (HFS-246), Food and Drug Administration, 
    200 C St. SW., Washington, DC 20204, 202-418-3005.
        For information regarding medical devices and radiological health: 
    Mervin O. Parker, Center for Devices and Radiological Health (HFZ-402), 
    Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 
    20850, 301-594-2186.
    SUPPLEMENTARY INFORMATION: In the Federal Register of April 3, 1996 (61 
    FR 14922) (republished on May 1, 1996 (61 FR 19476)), FDA published a 
    proposed rule to amend its regulations governing compliance with the 
    National Environmental Policy Act of 1969 (NEPA) as implemented by the 
    regulations of the Council on Environmental Quality. The primary 
    purpose of the proposed rule is to increase the efficiency of FDA's 
    implementation of NEPA and reduce the number of NEPA evaluations by 
    providing for categorical exclusions for additional classes of actions 
    that do not individually or cumulatively have a significant effect on 
    the human environment and for which, therefore, neither an 
    environmental impact statement nor an environmental assessment (EA) is 
    required. The proposed rule was issued in response to an initiative 
    announced in the President's National Performance Reports, 
    ``Reinventing Drug and Medical Device Regulations,'' April 1995, and 
    ``Reinventing Food Regulations,'' January 1996. The proposal gave 
    interested persons the opportunity to submit written comments until 
    July 2, 1996.
        One of the categorical exclusions included in the proposed rule is 
    a categorical exclusion for an ``[a]ction on an NDA [new drug 
    application], abbreviated application, or a supplement to such 
    application, or action on an OTC [over-the-counter] monograph, if the 
    action increases the use of the active moiety, but the concentration of 
    the substance in the environment will be below 1 part per billion 
    [ppb].'' (See proposed Sec. 25.31(b) (61 FR 19476 at 19492).) The 
    agency proposed this categorical exclusion because FDA has determined 
    that such actions for which concentrations of the substance in the 
    environment from use and disposal will be below 1 ppb ordinarily do not 
    have a significant effect on the environment. If there are specific 
    environmental concerns beyond those relating to use and disposal, for 
    example sourcing, FDA may give a specific action further environmental 
    consideration.
        On July 2, 1996, FDA received a request from Edward Lee Rogers, on 
    behalf of the Oregon Natural Resources Council Fund and the Oregon 
    Natural Resources Council Action, to extend the comment period to 
    permit comment on the ``underlying data upon which FDA relies for the 
    claimed adequacy and appropriateness of that [1 ppb] criteria.''
        FDA considered this request and has decided to add information to 
    the administrative record and reopen the comment period. FDA has added 
    to the administrative record a report on the ``Retrospective Review of 
    Ecotoxicity Data Submitted in Environmental Assessments.'' This report 
    summarizes the ecotoxicity data that supports the Center for Drug 
    Evaluation and Research's (CDER's) proposal to categorically exclude 
    actions on an NDA, abbreviated application, or a supplement to such 
    application, or action on an OTC monograph, if the action increases the 
    use of the active moiety, but the concentration of the substance in the 
    environment will be below 1 ppb. FDA has also added to the 
    administrative record an index of the petitions and actions that 
    support certain categorical exclusions for foods,
    
    [[Page 54747]]
    
    food additives and color additives in the proposed rule.
        The agency is reopening the comment period to ensure that the 
    public has an opportunity to comment on the data that support the 
    proposed categorical exclusions set forth in Secs. 25.31(b) and 
    25.32(i), (j), (k), (l), (m), (q), and (r).
        FDA believes that 30 days to comment is ample in this case, because 
    the agency is specifically limiting its reopening of the comment period 
    to comments on the categorical exclusions for which information has 
    been added to the administrative record. Furthermore, data from EA's 
    and findings of no significant impact for approved applications that 
    support FDA's proposed categorical exclusions have always been 
    available to the public upon request. Comments are invited, and will be 
    considered, only to the extent they are focused on the categorical 
    exclusions supported by information that has been added to the 
    administrative record and only to the extent the comments regarding 
    such information raise new issues not already raised by the person 
    submitting the comment.
        The documents that the agency is adding to the record are as 
    follows:
        1. ``Retrospective Review of Ecotoxicity Data Submitted in 
    Environmental Assessments,'' CDER, FDA.
        2. Index of Petitions and Actions Supporting Categorical Exclusions 
    for Foods, Food Additives, and Color Additives in proposed 21 CFR part 
    25.
        Interested persons may, on or before November 21, 1996, submit to 
    the Dockets Management Branch (address above) written comments 
    regarding the documents listed above. Two copies of any comments are to 
    be submitted, except that individuals may submit one copy. Comments are 
    to be identified with the docket number found in brackets in the 
    heading of this document. Received comments may be seen in the office 
    above between 9 a.m. and 4 p.m., Monday through Friday.
    
        Dated: October 16, 1996.
    William K. Hubbard,
    Associate Commissioner for Policy Coordination.
    [FR Doc. 96-27022 Filed 10-21-96; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
10/22/1996
Department:
Food and Drug Administration
Entry Type:
Proposed Rule
Action:
Proposed rule; reopening of comment period.
Document Number:
96-27022
Dates:
Written comments must be received by or postmarked on or before November 21, 1996. Comments postmarked after such date will not be considered.
Pages:
54746-54747 (2 pages)
Docket Numbers:
Docket No. 96N-0057
PDF File:
96-27022.pdf
CFR: (1)
21 CFR 25